Fresenius Medical Care AG (FMS) EBITDA (2009 - 2025)

Fresenius Medical Care AG (FMS) has reported EBITDA for 17 consecutive years, with $4.4 billion the latest figure, recorded in Q4 2025.

• In Q4 2025, EBITDA rose 24.02% year-over-year to $4.4 billion; the TTM figure through Dec 2025 stood at $6.7 billion (up 7.76% YoY), while the FY2025 annual figure was $4.4 billion, up 20.51% from the prior year.
• EBITDA came in at $4.4 billion for Q4 2025 at Fresenius Medical Care AG, up from $557.1 million in the prior quarter.
• The five-year high for EBITDA was $4.4 billion in Q4 2025, with the low at $557.1 million in Q3 2025.
• Average EBITDA over 5 years is $1.2 billion, with a median of $890.6 million recorded in 2024.
• Across the five-year window, EBITDA jumped 289.48% in 2024 and sank 38.74% in 2025, its largest moves.
• Year by year, EBITDA stood at $1.0 billion in 2021, then retreated by 14.74% to $864.1 million in 2022, then increased by 6.33% to $918.9 million in 2023, then surged by 289.48% to $3.6 billion in 2024, then grew by 24.02% to $4.4 billion in 2025.
• According to Business Quant data, EBITDA over the past three periods registered $4.4 billion, $557.1 million, and $906.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.